Skip to main content
Erschienen in: Current Bladder Dysfunction Reports 4/2016

07.11.2016 | Post-Prostatectomy and Acquired Voiding Dysfunction (V Tse, Section Editor)

Interstitial Cystitis/Bladder Pain Syndrome: a Review and an Update

verfasst von: Zhiwei Fang, Kexin Xu

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic condition characterized by pelvic pain and lower urinary tract symptoms. The evolution of nomenclature of IC/BPS has experienced a long history. The disease etiology is not yet fully understood; potential pathophysiologic causes proposed include defect of layer of glycosaminoglycan (GAG) on the apical surface of bladder floor; autoimmune, inflammatory, and neurogenic mechanisms; infection; and so on. There are a lot of strategies to cure IC/BPS, mainly including behavioral therapy, oral medicines, intravesical treatments, and intradetrusor botulinum toxin A (BTXA) injection. But none of them is curative. Most treatments are aimed at controlling symptom and improving the quality of life of patients. In this article, we will talk about the new progress of definition, etiology, and treatment on IC/BPS.
Literatur
1.
Zurück zum Zitat The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Society. The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Society.
2.
Zurück zum Zitat Oravisto KJ. Epidemiology of interstitial cystitis. Annales chirurgiae et gynaecologiae Fenniae. 1974. Oravisto KJ. Epidemiology of interstitial cystitis. Annales chirurgiae et gynaecologiae Fenniae. 1974.
3.
Zurück zum Zitat CK Payne GFJ, M Wise JQC. Interstitial cystitis and painful bladder syndrome. 2007. CK Payne GFJ, M Wise JQC. Interstitial cystitis and painful bladder syndrome. 2007.
4.
Zurück zum Zitat JQ Clemens RTM, MCOK ROSETTI SYG. Prevalence and incidence of interstitial cystitis in a managed care population. 2005. JQ Clemens RTM, MCOK ROSETTI SYG. Prevalence and incidence of interstitial cystitis in a managed care population. 2005.
5.
Zurück zum Zitat SH Berry LMB, C Pham KL, Nyberg L. Development, validation and testing of an epidemiological case definition of interstitial cystitis/painful bladder syndrome. 2010. SH Berry LMB, C Pham KL, Nyberg L. Development, validation and testing of an epidemiological case definition of interstitial cystitis/painful bladder syndrome. 2010.
6.
Zurück zum Zitat AM Suskind SHB, BA Ewing MNE. The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND Interstitial Cystitis Epidemiology male study. 2013. AM Suskind SHB, BA Ewing MNE. The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND Interstitial Cystitis Epidemiology male study. 2013.
7.
Zurück zum Zitat Berry SH, Elliott MN, Suttorp M, et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol. 2011;186(2):540–4.CrossRefPubMedPubMedCentral Berry SH, Elliott MN, Suttorp M, et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol. 2011;186(2):540–4.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Krieger JN, Riley DE, Cheah PY, Liong ML, Yuen KH. Epidemiology of prostatitis: new evidence for a world-wide problem. World J Urol. 2003;21(2):70–4.CrossRefPubMed Krieger JN, Riley DE, Cheah PY, Liong ML, Yuen KH. Epidemiology of prostatitis: new evidence for a world-wide problem. World J Urol. 2003;21(2):70–4.CrossRefPubMed
9.
Zurück zum Zitat Clemens JQ, Meenan RT, O’Keeffe-Rosetti MC, Gao SY, Brown SO, Calhoun EA. Prevalence of prostatitis-like symptoms in a managed care population. J Urol. 2006;176(2):593–6. discussion 596.CrossRefPubMed Clemens JQ, Meenan RT, O’Keeffe-Rosetti MC, Gao SY, Brown SO, Calhoun EA. Prevalence of prostatitis-like symptoms in a managed care population. J Urol. 2006;176(2):593–6. discussion 596.CrossRefPubMed
10.
Zurück zum Zitat Mehik A, Hellstrom P, Lukkarinen O, Sarpola A, Jarvelin M. Epidemiology of prostatitis in Finnish men: a population-based cross-sectional study. BJU Int. 2000;86(4):443–8.CrossRefPubMed Mehik A, Hellstrom P, Lukkarinen O, Sarpola A, Jarvelin M. Epidemiology of prostatitis in Finnish men: a population-based cross-sectional study. BJU Int. 2000;86(4):443–8.CrossRefPubMed
11.
Zurück zum Zitat Skene A. Diseases of the bladder and urethra in women. Am J Med Sci. 1879. Skene A. Diseases of the bladder and urethra in women. Am J Med Sci. 1879.
12.
Zurück zum Zitat Hünner GL. A rare type of bladder ulcer in women. Tr. South. Surg. Gynecol. Assoc.. 1914. Hünner GL. A rare type of bladder ulcer in women. Tr. South. Surg. Gynecol. Assoc.. 1914.
13.
Zurück zum Zitat DJ Clauw MS, D Radulovic AS. The relationship between fibromyalgia and interstitial cystitis. 1997. DJ Clauw MS, D Radulovic AS. The relationship between fibromyalgia and interstitial cystitis. 1997.
14.
Zurück zum Zitat Hanno PM, Landis JR, Matthews-Cook Y, Kusek J, Nyberg Jr L. The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health Interstitial Cystitis Database study. J Urol. 1999;161(2):553–7.CrossRefPubMed Hanno PM, Landis JR, Matthews-Cook Y, Kusek J, Nyberg Jr L. The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health Interstitial Cystitis Database study. J Urol. 1999;161(2):553–7.CrossRefPubMed
15.
Zurück zum Zitat •Gillenwater JY, Wein AJ. Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28–29, 1987. J Urol. 1988;140(1):203–6. Covers the classic criteria of interstitial cystitis/bladder pain syndrome (IC/BPS).PubMed •Gillenwater JY, Wein AJ. Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28–29, 1987. J Urol. 1988;140(1):203–6. Covers the classic criteria of interstitial cystitis/bladder pain syndrome (IC/BPS).PubMed
16.
Zurück zum Zitat Hanno P, Dmochowski R. Status of international consensus on interstitial cystitis/bladder pain syndrome/painful bladder syndrome: 2008 snapshot. Neurourol Urodyn. 2009;28(4):274–86.CrossRefPubMed Hanno P, Dmochowski R. Status of international consensus on interstitial cystitis/bladder pain syndrome/painful bladder syndrome: 2008 snapshot. Neurourol Urodyn. 2009;28(4):274–86.CrossRefPubMed
17.
Zurück zum Zitat van de Merwe JP, Nordling J, Bouchelouche P, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60–7.CrossRefPubMed van de Merwe JP, Nordling J, Bouchelouche P, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60–7.CrossRefPubMed
18.
Zurück zum Zitat Ito T, Ueda T, Honma Y, Takei M. Recent trends in patient characteristics and therapeutic choices for interstitial cystitis: analysis of 282 Japanese patients. Int J Urol. 2007;14(12):1068–70.CrossRefPubMed Ito T, Ueda T, Honma Y, Takei M. Recent trends in patient characteristics and therapeutic choices for interstitial cystitis: analysis of 282 Japanese patients. Int J Urol. 2007;14(12):1068–70.CrossRefPubMed
19.
Zurück zum Zitat •Homma Y. Hypersensitive bladder: a solution to confused terminology and ignorance concerning interstitial cystitis. Int J Urol. 2014;21 Suppl 1:43–7. Article covers new term drawing a distinction between interstitial cystitis and IC-like patients.CrossRefPubMed •Homma Y. Hypersensitive bladder: a solution to confused terminology and ignorance concerning interstitial cystitis. Int J Urol. 2014;21 Suppl 1:43–7. Article covers new term drawing a distinction between interstitial cystitis and IC-like patients.CrossRefPubMed
20.
Zurück zum Zitat Hicks RM, Ketterer B, Warren RC. The ultrastructure and chemistry of the luminal plasma membrane of the mammalian urinary bladder: a structure with low permeability to water and ions. Philos Trans R Soc Lond B Biol Sci. 1974;268(891):23–38.CrossRefPubMed Hicks RM, Ketterer B, Warren RC. The ultrastructure and chemistry of the luminal plasma membrane of the mammalian urinary bladder: a structure with low permeability to water and ions. Philos Trans R Soc Lond B Biol Sci. 1974;268(891):23–38.CrossRefPubMed
21.
Zurück zum Zitat Hurst RE, Meerveld BG, Wisniewski AB, et al. Increased bladder permeability in interstitial cystitis/painful bladder syndrome. Transl Androl Urol. 2015;4(5):563–71.PubMedPubMedCentral Hurst RE, Meerveld BG, Wisniewski AB, et al. Increased bladder permeability in interstitial cystitis/painful bladder syndrome. Transl Androl Urol. 2015;4(5):563–71.PubMedPubMedCentral
22.
Zurück zum Zitat ••Kreft ME, Sterle M, Veranic P, Jezernik K. Urothelial injuries and the early wound healing response: tight junctions and urothelial cytodifferentiation. Histochem Cell Biol. 2005;123(4–5):529–39. Defect of GAG layer is the most famous hypothesis of IC/BPS, and it provides theoretical basis for GAG layer replenishment treatment.CrossRefPubMed ••Kreft ME, Sterle M, Veranic P, Jezernik K. Urothelial injuries and the early wound healing response: tight junctions and urothelial cytodifferentiation. Histochem Cell Biol. 2005;123(4–5):529–39. Defect of GAG layer is the most famous hypothesis of IC/BPS, and it provides theoretical basis for GAG layer replenishment treatment.CrossRefPubMed
23.
Zurück zum Zitat Varley CL, Garthwaite MA, Cross W, Hinley J, Trejdosiewicz LK, Southgate J. PPARgamma-regulated tight junction development during human urothelial cytodifferentiation. J Cell Physiol. 2006;208(2):407–17.CrossRefPubMedPubMedCentral Varley CL, Garthwaite MA, Cross W, Hinley J, Trejdosiewicz LK, Southgate J. PPARgamma-regulated tight junction development during human urothelial cytodifferentiation. J Cell Physiol. 2006;208(2):407–17.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Buckley MS, Washington S, Laurent C, Erickson DR, Bhavananadan VP. Characterization and immunohistochemical localization of the glycoconjugates of the rabbit bladder mucosa. Arch Biochem Biophys. 1996;330(1):163–73.CrossRefPubMed Buckley MS, Washington S, Laurent C, Erickson DR, Bhavananadan VP. Characterization and immunohistochemical localization of the glycoconjugates of the rabbit bladder mucosa. Arch Biochem Biophys. 1996;330(1):163–73.CrossRefPubMed
25.
Zurück zum Zitat Stanford EJ, Dell JR, Parsons CL. The emerging presence of interstitial cystitis in gynecologic patients with chronic pelvic pain. Urology. 2007;69(4 Suppl):53–9.CrossRefPubMed Stanford EJ, Dell JR, Parsons CL. The emerging presence of interstitial cystitis in gynecologic patients with chronic pelvic pain. Urology. 2007;69(4 Suppl):53–9.CrossRefPubMed
26.
Zurück zum Zitat Buffington CA, Woodworth BE. Excretion of fluorescein in the urine of women with interstitial cystitis. J Urol. 1997;158(3 Pt 1):786–9.CrossRefPubMed Buffington CA, Woodworth BE. Excretion of fluorescein in the urine of women with interstitial cystitis. J Urol. 1997;158(3 Pt 1):786–9.CrossRefPubMed
27.
Zurück zum Zitat Janssen DA, van Wijk XM, Jansen KC, van Kuppevelt TH, Heesakkers JP, Schalken JA. The distribution and function of chondroitin sulfate and other sulfated glycosaminoglycans in the human bladder and their contribution to the protective bladder barrier. J Urol. 2013;189(1):336–42.CrossRefPubMed Janssen DA, van Wijk XM, Jansen KC, van Kuppevelt TH, Heesakkers JP, Schalken JA. The distribution and function of chondroitin sulfate and other sulfated glycosaminoglycans in the human bladder and their contribution to the protective bladder barrier. J Urol. 2013;189(1):336–42.CrossRefPubMed
28.
Zurück zum Zitat Erickson DR, Herb N, Ordille S, Harmon N. A new direct test of bladder permeability. J Urol. 2000;164:419–22.CrossRefPubMed Erickson DR, Herb N, Ordille S, Harmon N. A new direct test of bladder permeability. J Urol. 2000;164:419–22.CrossRefPubMed
29.
Zurück zum Zitat Towner RA, Wisniewski AB, Wu DH, et al. A feasibility study to determine whether clinical contrast enhanced magnetic resonance imaging can detect increased bladder permeability in patients with interstitial cystitis. J Urol. 2015. Towner RA, Wisniewski AB, Wu DH, et al. A feasibility study to determine whether clinical contrast enhanced magnetic resonance imaging can detect increased bladder permeability in patients with interstitial cystitis. J Urol. 2015.
30.
Zurück zum Zitat Johansson SL, Fall M. Clinical features and spectrum of light microscopic changes in interstitial cystitis. J Urol. 1990. Johansson SL, Fall M. Clinical features and spectrum of light microscopic changes in interstitial cystitis. J Urol. 1990.
31.
Zurück zum Zitat Said JW, Van de Velve R, Gillespie L. Immunopathology of interstitial cystitis. 1989. Said JW, Van de Velve R, Gillespie L. Immunopathology of interstitial cystitis. 1989.
32.
Zurück zum Zitat Keay S, Zhang CO, Trifillis AL, Hebel JR, Jacobs SC. Urine autoantibodies in interstitial cystitis. 1997. Keay S, Zhang CO, Trifillis AL, Hebel JR, Jacobs SC. Urine autoantibodies in interstitial cystitis. 1997.
33.
Zurück zum Zitat Altuntas CZ, Daneshgari F, Sakalar C, Goksoy E. Autoimmunity to uroplakin II causes cystitis in mice: a novel model of interstitial cystitis. Eur Urol. 2012;61:193–200.CrossRefPubMed Altuntas CZ, Daneshgari F, Sakalar C, Goksoy E. Autoimmunity to uroplakin II causes cystitis in mice: a novel model of interstitial cystitis. Eur Urol. 2012;61:193–200.CrossRefPubMed
34.
Zurück zum Zitat Izgi K, Altuntas CZ, Bicer F, et al. Uroplakin peptide-specific autoimmunity initiates interstitial cystitis/painful bladder syndrome in mice. PLoS One. 2013;8(8), e72067.CrossRefPubMedPubMedCentral Izgi K, Altuntas CZ, Bicer F, et al. Uroplakin peptide-specific autoimmunity initiates interstitial cystitis/painful bladder syndrome in mice. PLoS One. 2013;8(8), e72067.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Carter HB. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale. BJU Int. 2013;112(5):543–7.CrossRefPubMed Carter HB. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale. BJU Int. 2013;112(5):543–7.CrossRefPubMed
36.
Zurück zum Zitat Peters KM, Killinger KA, Ibrahim IA. Childhood symptoms and events in women with interstitial cystitis/painful bladder syndrome. Urology. 2009;73(2):258–62.CrossRefPubMed Peters KM, Killinger KA, Ibrahim IA. Childhood symptoms and events in women with interstitial cystitis/painful bladder syndrome. Urology. 2009;73(2):258–62.CrossRefPubMed
37.
Zurück zum Zitat Warren JW, Brown V, Jacobs S, Horne L, Langenberg P, Greenberg P. Urinary tract infection and inflammation at onset of interstitial cystitis/painful bladder syndrome. Urology. 2008;71(6):1085–90.CrossRefPubMed Warren JW, Brown V, Jacobs S, Horne L, Langenberg P, Greenberg P. Urinary tract infection and inflammation at onset of interstitial cystitis/painful bladder syndrome. Urology. 2008;71(6):1085–90.CrossRefPubMed
38.
Zurück zum Zitat Zhang QH, Shen XC, Zhou ZS, Chen ZW, Lu GS, Song B. Decreased nanobacteria levels and symptoms of nanobacteria-associated interstitial cystitis/painful bladder syndrome after tetracycline treatment. Int Urogynecol J. 2010;21(1):103–9.CrossRefPubMed Zhang QH, Shen XC, Zhou ZS, Chen ZW, Lu GS, Song B. Decreased nanobacteria levels and symptoms of nanobacteria-associated interstitial cystitis/painful bladder syndrome after tetracycline treatment. Int Urogynecol J. 2010;21(1):103–9.CrossRefPubMed
40.
Zurück zum Zitat Verit A, Guner ND. Helicobacter pylori and urinary system stones: endoluminal damage as sub-hypothesis to support the current stone theory. Med Hypotheses. 2014;83(6):677–80.CrossRefPubMed Verit A, Guner ND. Helicobacter pylori and urinary system stones: endoluminal damage as sub-hypothesis to support the current stone theory. Med Hypotheses. 2014;83(6):677–80.CrossRefPubMed
41.
Zurück zum Zitat Staack A, Distelberg B, Schlaifer A, Sabate J. Prospective study on the effects of regular and decaffeinated coffee on urinary symptoms in young and healthy volunteers. Neurourol Urodyn. 2015. Staack A, Distelberg B, Schlaifer A, Sabate J. Prospective study on the effects of regular and decaffeinated coffee on urinary symptoms in young and healthy volunteers. Neurourol Urodyn. 2015.
42.
Zurück zum Zitat AN Pierce JAC. Chapter seventeen—stress and chronic pelvic pain. Progress in molecular biology and translational science. 2015. AN Pierce JAC. Chapter seventeen—stress and chronic pelvic pain. Progress in molecular biology and translational science. 2015.
43.
Zurück zum Zitat Lee UJ, Ackerman AL, Wu A, et al. Chronic psychological stress in high-anxiety rats induces sustained bladder hyperalgesia. Physiol Behav. 2015;139:541–8.CrossRefPubMed Lee UJ, Ackerman AL, Wu A, et al. Chronic psychological stress in high-anxiety rats induces sustained bladder hyperalgesia. Physiol Behav. 2015;139:541–8.CrossRefPubMed
44.
Zurück zum Zitat Foster Jr HE, Hanno PM, Nickel JC, et al. Effect of amitriptyline on symptoms in treatment naive patients with interstitial cystitis/painful bladder syndrome. J Urol. 2010;183(5):1853–8.CrossRefPubMedPubMedCentral Foster Jr HE, Hanno PM, Nickel JC, et al. Effect of amitriptyline on symptoms in treatment naive patients with interstitial cystitis/painful bladder syndrome. J Urol. 2010;183(5):1853–8.CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Dinis S, de Oliveira JT, Pinto R, Cruz F, Buffington CT, Dinis P. From bladder to systemic syndrome: concept and treatment evolution of interstitial cystitis. Int J Womens Health. 2015;7:735–44.CrossRefPubMedPubMedCentral Dinis S, de Oliveira JT, Pinto R, Cruz F, Buffington CT, Dinis P. From bladder to systemic syndrome: concept and treatment evolution of interstitial cystitis. Int J Womens Health. 2015;7:735–44.CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Yang W, Propert KJ, Richard LJ. Estimating the efficacy of an interstitial cystitis/painful bladder syndrome medication in a randomized trial with both non-adherence and loss to follow-up. Stat Med. 2014;33(20):3547–55.CrossRefPubMed Yang W, Propert KJ, Richard LJ. Estimating the efficacy of an interstitial cystitis/painful bladder syndrome medication in a randomized trial with both non-adherence and loss to follow-up. Stat Med. 2014;33(20):3547–55.CrossRefPubMed
47.
Zurück zum Zitat Sun Y, Fang Z, Ding Q, Zheng J. Effect of amitriptyline in treatment interstitial cystitis or bladder pain syndrome according to two criteria: does ESSIC criteria change the response rate. Neurourol Urodyn. 2014;33(3):341–4.CrossRefPubMed Sun Y, Fang Z, Ding Q, Zheng J. Effect of amitriptyline in treatment interstitial cystitis or bladder pain syndrome according to two criteria: does ESSIC criteria change the response rate. Neurourol Urodyn. 2014;33(3):341–4.CrossRefPubMed
48.
Zurück zum Zitat Holm-Bentzen M, Jacobsen F, Nerstrom B, et al. A prospective double-blind clinically controlled multicenter trial of sodium pentosanpolysulfate in the treatment of interstitial cystitis and related painful bladder disease. J Urol. 1987;138(3):503–7.PubMed Holm-Bentzen M, Jacobsen F, Nerstrom B, et al. A prospective double-blind clinically controlled multicenter trial of sodium pentosanpolysulfate in the treatment of interstitial cystitis and related painful bladder disease. J Urol. 1987;138(3):503–7.PubMed
49.
Zurück zum Zitat Sant GR, Propert KJ, Hanno PM, et al. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol. 2003;170(3):810–5.CrossRefPubMed Sant GR, Propert KJ, Hanno PM, et al. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol. 2003;170(3):810–5.CrossRefPubMed
50.
Zurück zum Zitat Mulholland SG, Hanno P, Parsons CL, Sant GR, Staskin DR. Pentosan polysulfate sodium for therapy of interstitial cystitis. A double-blind placebo-controlled clinical study. Urology. 1990;35(6):552–8.CrossRefPubMed Mulholland SG, Hanno P, Parsons CL, Sant GR, Staskin DR. Pentosan polysulfate sodium for therapy of interstitial cystitis. A double-blind placebo-controlled clinical study. Urology. 1990;35(6):552–8.CrossRefPubMed
51.
Zurück zum Zitat Parsons CL, Benson G, Childs SJ, Hanno P, Sant GR, Webster G. A quantitatively controlled method to study prospectively interstitial cystitis and demonstrate the efficacy of pentosanpolysulfate. J Urol. 1993;150(3):845–8.PubMed Parsons CL, Benson G, Childs SJ, Hanno P, Sant GR, Webster G. A quantitatively controlled method to study prospectively interstitial cystitis and demonstrate the efficacy of pentosanpolysulfate. J Urol. 1993;150(3):845–8.PubMed
52.
Zurück zum Zitat Nickel JC, Herschorn S, Whitmore KE, et al. Pentosan polysulfate sodium for treatment of interstitial cystitis/bladder pain syndrome: insights from a randomized, double-blind, placebo controlled study. J Urol. 2015;193(3):857–62.CrossRefPubMed Nickel JC, Herschorn S, Whitmore KE, et al. Pentosan polysulfate sodium for treatment of interstitial cystitis/bladder pain syndrome: insights from a randomized, double-blind, placebo controlled study. J Urol. 2015;193(3):857–62.CrossRefPubMed
53.
Zurück zum Zitat Giannantoni A, Bini V, Dmochowski R, et al. Contemporary management of the painful bladder: a systematic review. Eur Urol. 2012;61(1):29–53.CrossRefPubMed Giannantoni A, Bini V, Dmochowski R, et al. Contemporary management of the painful bladder: a systematic review. Eur Urol. 2012;61(1):29–53.CrossRefPubMed
54.
Zurück zum Zitat Perez-Marrero R, Emerson LE, Feltis JT. A controlled study of dimethyl sulfoxide in interstitial cystitis. J Urol. 1988;140(1):36–9.PubMed Perez-Marrero R, Emerson LE, Feltis JT. A controlled study of dimethyl sulfoxide in interstitial cystitis. J Urol. 1988;140(1):36–9.PubMed
55.
Zurück zum Zitat Yamada Y, Nomiya A, Niimi A, et al. A survey on clinical practice of interstitial cystitis in Japan. Transl Androl Urol. 2015;4(5):486–90.PubMedPubMedCentral Yamada Y, Nomiya A, Niimi A, et al. A survey on clinical practice of interstitial cystitis in Japan. Transl Androl Urol. 2015;4(5):486–90.PubMedPubMedCentral
56.
Zurück zum Zitat Neuhaus J, Schwalenberg T. Intravesical treatments of bladder pain syndrome/interstitial cystitis. Nat Rev Urol. 2012;9(12):707–20.CrossRefPubMed Neuhaus J, Schwalenberg T. Intravesical treatments of bladder pain syndrome/interstitial cystitis. Nat Rev Urol. 2012;9(12):707–20.CrossRefPubMed
57.
Zurück zum Zitat Tomoe H. In what type of interstitial cystitis/bladder pain syndrome is DMSO intravesical instillation therapy effective. Transl Androl Urol. 2015;4(6):600–4.PubMedPubMedCentral Tomoe H. In what type of interstitial cystitis/bladder pain syndrome is DMSO intravesical instillation therapy effective. Transl Androl Urol. 2015;4(6):600–4.PubMedPubMedCentral
58.
Zurück zum Zitat Peeker R, Haghsheno MA, Holmang S, Fall M. Intravesical bacillus Calmette-Guerin and dimethyl sulfoxide for treatment of classic and nonulcer interstitial cystitis: a prospective, randomized double-blind study. J Urol. 2000;164(6):1912–5. discussion 1915–6.CrossRefPubMed Peeker R, Haghsheno MA, Holmang S, Fall M. Intravesical bacillus Calmette-Guerin and dimethyl sulfoxide for treatment of classic and nonulcer interstitial cystitis: a prospective, randomized double-blind study. J Urol. 2000;164(6):1912–5. discussion 1915–6.CrossRefPubMed
59.
Zurück zum Zitat Tomoe H. Editorial Comment from Dr Tomoe to botulinum toxin type A injection for refractory interstitial cystitis: a randomized comparative study and predictors of treatment response. Int J Urol. 2015;22(9):841–2.CrossRefPubMed Tomoe H. Editorial Comment from Dr Tomoe to botulinum toxin type A injection for refractory interstitial cystitis: a randomized comparative study and predictors of treatment response. Int J Urol. 2015;22(9):841–2.CrossRefPubMed
60.
Zurück zum Zitat Stav K, Beberashvili I, Lindner A, Leibovici D. Predictors of response to intravesical dimethyl-sulfoxide cocktail in patients with interstitial cystitis. Urology. 2012;80(1):61–5.CrossRefPubMed Stav K, Beberashvili I, Lindner A, Leibovici D. Predictors of response to intravesical dimethyl-sulfoxide cocktail in patients with interstitial cystitis. Urology. 2012;80(1):61–5.CrossRefPubMed
61.
Zurück zum Zitat Hung MJ, Chen YT, Shen PS, Hsu ST, Chen GD, Ho ES. Risk factors that affect the treatment of interstitial cystitis using intravesical therapy with a dimethyl sulfoxide cocktail. Int Urogynecol J. 2012;23(11):1533–9.CrossRefPubMed Hung MJ, Chen YT, Shen PS, Hsu ST, Chen GD, Ho ES. Risk factors that affect the treatment of interstitial cystitis using intravesical therapy with a dimethyl sulfoxide cocktail. Int Urogynecol J. 2012;23(11):1533–9.CrossRefPubMed
62.
Zurück zum Zitat Gafni-Kane A, Botros SM, Du H, Sand RI, Sand PK. Measuring the success of combined intravesical dimethyl sulfoxide and triamcinolone for treatment of bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2013;24(2):303–11.CrossRefPubMed Gafni-Kane A, Botros SM, Du H, Sand RI, Sand PK. Measuring the success of combined intravesical dimethyl sulfoxide and triamcinolone for treatment of bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2013;24(2):303–11.CrossRefPubMed
63.
Zurück zum Zitat Cervigni M. Interstitial cystitis/bladder pain syndrome and glycosaminoglycans replacement therapy. Transl Androl Urol. 2015;4(6):638–42.PubMedPubMedCentral Cervigni M. Interstitial cystitis/bladder pain syndrome and glycosaminoglycans replacement therapy. Transl Androl Urol. 2015;4(6):638–42.PubMedPubMedCentral
64.
Zurück zum Zitat Morales A, Emerson L, Nickel JC. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. Urology. 1997;49(5A Suppl):111–3.CrossRefPubMed Morales A, Emerson L, Nickel JC. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. Urology. 1997;49(5A Suppl):111–3.CrossRefPubMed
65.
Zurück zum Zitat Rooney P, Srivastava A, Watson L, Quinlan LR, Pandit A. Hyaluronic acid decreases IL-6 and IL-8 secretion and permeability in an inflammatory model of interstitial cystitis. Acta Biomater. 2015;19:66–75.CrossRefPubMed Rooney P, Srivastava A, Watson L, Quinlan LR, Pandit A. Hyaluronic acid decreases IL-6 and IL-8 secretion and permeability in an inflammatory model of interstitial cystitis. Acta Biomater. 2015;19:66–75.CrossRefPubMed
66.
Zurück zum Zitat Engelhardt PF, Morakis N, Daha LK, Esterbauer B, Riedl CR. Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2011;22(4):401–5.CrossRefPubMed Engelhardt PF, Morakis N, Daha LK, Esterbauer B, Riedl CR. Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2011;22(4):401–5.CrossRefPubMed
67.
Zurück zum Zitat Parsons CL, Koziol JA, Proctor JG, Zupkas P, Argade S. Heparin and alkalinized lidocaine versus alkalinized lidocaine for treatment of interstitial cystitis symptoms. Can J Urol. 2015;22(2):7739–44.PubMed Parsons CL, Koziol JA, Proctor JG, Zupkas P, Argade S. Heparin and alkalinized lidocaine versus alkalinized lidocaine for treatment of interstitial cystitis symptoms. Can J Urol. 2015;22(2):7739–44.PubMed
68.
Zurück zum Zitat Negrete HO, Lavelle JP, Berg J, Lewis SA, Zeidel ML. Permeability properties of the intact mammalian bladder epithelium. Am J Physiol. 1996;271(4 Pt 2):F886–94.PubMed Negrete HO, Lavelle JP, Berg J, Lewis SA, Zeidel ML. Permeability properties of the intact mammalian bladder epithelium. Am J Physiol. 1996;271(4 Pt 2):F886–94.PubMed
69.
Zurück zum Zitat Henry RA, Morales A, Cahill CM. Beyond a simple anesthetic effect: lidocaine in the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Urology. 2015;85(5):1025–33.CrossRefPubMed Henry RA, Morales A, Cahill CM. Beyond a simple anesthetic effect: lidocaine in the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Urology. 2015;85(5):1025–33.CrossRefPubMed
70.
Zurück zum Zitat Nomiya A, Naruse T, Niimi A, et al. On- and post-treatment symptom relief by repeated instillations of heparin and alkalized lidocaine in interstitial cystitis. Int J Urol. 2013;20(11):1118–22.CrossRefPubMed Nomiya A, Naruse T, Niimi A, et al. On- and post-treatment symptom relief by repeated instillations of heparin and alkalized lidocaine in interstitial cystitis. Int J Urol. 2013;20(11):1118–22.CrossRefPubMed
71.
Zurück zum Zitat Welk BK, Teichman JM. Dyspareunia response in patients with interstitial cystitis treated with intravesical lidocaine, bicarbonate, and heparin. Urology. 2008;71(1):67–70.CrossRefPubMed Welk BK, Teichman JM. Dyspareunia response in patients with interstitial cystitis treated with intravesical lidocaine, bicarbonate, and heparin. Urology. 2008;71(1):67–70.CrossRefPubMed
72.
Zurück zum Zitat Parsons CL, Zupkas P, Proctor J, et al. Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis. J Sex Med. 2012;9(1):207–12.CrossRefPubMed Parsons CL, Zupkas P, Proctor J, et al. Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis. J Sex Med. 2012;9(1):207–12.CrossRefPubMed
73.
Zurück zum Zitat Jhang JF, Jiang YH, Kuo HC. Potential therapeutic effect of intravesical botulinum toxin type A on bladder pain syndrome/interstitial cystitis. Int J Urol. 2014;21 Suppl 1:49–55.CrossRefPubMed Jhang JF, Jiang YH, Kuo HC. Potential therapeutic effect of intravesical botulinum toxin type A on bladder pain syndrome/interstitial cystitis. Int J Urol. 2014;21 Suppl 1:49–55.CrossRefPubMed
74.
Zurück zum Zitat Smith CP, Boone TB, de Groat WC, Chancellor MB, Somogyi GT. Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Res Bull. 2003;61(2):165–71.CrossRefPubMed Smith CP, Boone TB, de Groat WC, Chancellor MB, Somogyi GT. Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Res Bull. 2003;61(2):165–71.CrossRefPubMed
75.
Zurück zum Zitat Lucioni A, Bales GT, Lotan TL, McGehee DS, Cook SP, Rapp DE. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008;101(3):366–70.CrossRefPubMed Lucioni A, Bales GT, Lotan TL, McGehee DS, Cook SP, Rapp DE. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008;101(3):366–70.CrossRefPubMed
76.
Zurück zum Zitat Kuo HC, Jiang YH, Tsai YC, Kuo YC. Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment—a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol Urodyn. 2015. Kuo HC, Jiang YH, Tsai YC, Kuo YC. Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment—a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol Urodyn. 2015.
77.
Zurück zum Zitat Pinto R, Lopes T, Silva J, Silva C, DInis P. Clinical response to intra-trigonal onabotulinum toxin A injections is not related to the presence of ulcers in bladder pain syndrome/interstitial cystitis patient. 2013 AUA abstract. 2013. Pinto R, Lopes T, Silva J, Silva C, DInis P. Clinical response to intra-trigonal onabotulinum toxin A injections is not related to the presence of ulcers in bladder pain syndrome/interstitial cystitis patient. 2013 AUA abstract. 2013.
78.
Zurück zum Zitat HC Kuo MBC. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009 . HC Kuo MBC. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009 .
79.
Zurück zum Zitat Peng CH, Jhang JF, Shie JH, Kuo HC. Down regulation of vascular endothelial growth factor is associated with decreased inflammation after intravesical OnabotulinumtoxinA injections combined with hydrodistention for patients with interstitial cystitis—clinical results and immunohistochemistry analysis. Urology. 2013. 82(6): 1452.e1-6. Peng CH, Jhang JF, Shie JH, Kuo HC. Down regulation of vascular endothelial growth factor is associated with decreased inflammation after intravesical OnabotulinumtoxinA injections combined with hydrodistention for patients with interstitial cystitis—clinical results and immunohistochemistry analysis. Urology. 2013. 82(6): 1452.e1-6.
80.
Zurück zum Zitat Lee CL, Kuo HC. Long-term efficacy and safety of repeated intravescial onabotulinumtoxinA injections plus hydrodistention in the treatment of interstitial cystitis/bladder pain syndrome. Toxins (Basel). 2015;7(10):4283–93.CrossRef Lee CL, Kuo HC. Long-term efficacy and safety of repeated intravescial onabotulinumtoxinA injections plus hydrodistention in the treatment of interstitial cystitis/bladder pain syndrome. Toxins (Basel). 2015;7(10):4283–93.CrossRef
81.
Zurück zum Zitat Kuo HC. Repeated onabotulinumtoxin-a injections provide better results than single injection in treatment of painful bladder syndrome. Pain Physician. 2013;16(1):E15–23.PubMed Kuo HC. Repeated onabotulinumtoxin-a injections provide better results than single injection in treatment of painful bladder syndrome. Pain Physician. 2013;16(1):E15–23.PubMed
82.
Zurück zum Zitat Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology. 2004;64(5):871–5. discussion 875.CrossRefPubMed Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology. 2004;64(5):871–5. discussion 875.CrossRefPubMed
83.
Zurück zum Zitat Hanno PM, Sant GR. Clinical highlights of the National Institute of Diabetes and Digestive and Kidney Diseases/Interstitial Cystitis Association scientific conference on interstitial cystitis. Urology. 2001;57(6 Suppl 1):2–6.CrossRefPubMed Hanno PM, Sant GR. Clinical highlights of the National Institute of Diabetes and Digestive and Kidney Diseases/Interstitial Cystitis Association scientific conference on interstitial cystitis. Urology. 2001;57(6 Suppl 1):2–6.CrossRefPubMed
84.
Zurück zum Zitat Adamowicz J, Pokrywczynska M, Drewa T. Conditioned medium derived from mesenchymal stem cells culture as a intravesical therapy for cystitis interstitials. Med Hypotheses. 2014;82(6):670–3.CrossRefPubMed Adamowicz J, Pokrywczynska M, Drewa T. Conditioned medium derived from mesenchymal stem cells culture as a intravesical therapy for cystitis interstitials. Med Hypotheses. 2014;82(6):670–3.CrossRefPubMed
85.
Zurück zum Zitat Song M, Lim J, Yu HY, et al. Mesenchymal stem cell therapy alleviates interstitial cystitis by activating Wnt signaling pathway. Stem Cells Dev. 2015;24(14):1648–57.CrossRefPubMedPubMedCentral Song M, Lim J, Yu HY, et al. Mesenchymal stem cell therapy alleviates interstitial cystitis by activating Wnt signaling pathway. Stem Cells Dev. 2015;24(14):1648–57.CrossRefPubMedPubMedCentral
86.
Zurück zum Zitat Colaco MA, Evans RJ. Current recommendations for bladder instillation therapy in the treatment of interstitial cystitis/bladder pain syndrome. Curr Urol Rep. 2013;14(5):442–7.CrossRefPubMed Colaco MA, Evans RJ. Current recommendations for bladder instillation therapy in the treatment of interstitial cystitis/bladder pain syndrome. Curr Urol Rep. 2013;14(5):442–7.CrossRefPubMed
87.
Zurück zum Zitat Zacche MM, Srikrishna S, Cardozo L. Novel targeted bladder drug-delivery systems: a review. Res Rep Urol. 2015;7:169–78.PubMedPubMedCentral Zacche MM, Srikrishna S, Cardozo L. Novel targeted bladder drug-delivery systems: a review. Res Rep Urol. 2015;7:169–78.PubMedPubMedCentral
88.
Zurück zum Zitat Rajaganapathy BR, Chancellor MB, Nirmal J, Dang L, Tyagi P. Bladder uptake of liposomes after intravesical administration occurs by endocytosis. PLoS One. 2015;10(3), e0122766.CrossRefPubMedPubMedCentral Rajaganapathy BR, Chancellor MB, Nirmal J, Dang L, Tyagi P. Bladder uptake of liposomes after intravesical administration occurs by endocytosis. PLoS One. 2015;10(3), e0122766.CrossRefPubMedPubMedCentral
89.
Zurück zum Zitat Lander EB, See JR. Intravesical instillation of pentosan polysulfate encapsulated in a liposome nanocarrier for interstitial cystitis. Am J Clin Exp Urol. 2014;2(2):145–8.PubMedPubMedCentral Lander EB, See JR. Intravesical instillation of pentosan polysulfate encapsulated in a liposome nanocarrier for interstitial cystitis. Am J Clin Exp Urol. 2014;2(2):145–8.PubMedPubMedCentral
90.
Zurück zum Zitat Gong C, Qi T, Wei X, et al. Thermosensitive polymeric hydrogels as drug delivery systems. Curr Med Chem. 2013;20(1):79–94.CrossRefPubMed Gong C, Qi T, Wei X, et al. Thermosensitive polymeric hydrogels as drug delivery systems. Curr Med Chem. 2013;20(1):79–94.CrossRefPubMed
91.
Zurück zum Zitat Nickel JC, Jain P, Shore N, et al. Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device. Sci Transl Med. 2012;4(143):143ra100.CrossRefPubMed Nickel JC, Jain P, Shore N, et al. Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device. Sci Transl Med. 2012;4(143):143ra100.CrossRefPubMed
Metadaten
Titel
Interstitial Cystitis/Bladder Pain Syndrome: a Review and an Update
verfasst von
Zhiwei Fang
Kexin Xu
Publikationsdatum
07.11.2016
Verlag
Springer US
Erschienen in
Current Bladder Dysfunction Reports / Ausgabe 4/2016
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-016-0387-y

Weitere Artikel der Ausgabe 4/2016

Current Bladder Dysfunction Reports 4/2016 Zur Ausgabe

Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)

Neurogenic Bowel Dysfunction in Patients with Neurogenic Bladder

Neurogenic Bladder (C Powell, Section Editor)

Cystectomy for Neurogenic Bladder

Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)

Post Prostatectomy Bladder Dysfunction: Where Are We Now?

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.